Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

Journal of Clinical Oncology

Volumn 27, Issue 32, 2009, Pages 5363-5369

  Herrstedt, Jørn ^a   Apornwirat, Wichit ^a   Shaharyar, Ahmed ^a   Aziz, Zeba ^a   Roila, Fausto ^a   Van Belle, Simon ^a   Russo, Mark W ^a   Levin, Jeremey ^a   Ranganathan, Salabha ^a   Guckert, Mary ^a   Grunberg, Steven M ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CASOPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ONDANSETRON; PLACEBO; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; NEUROKININ 1 RECEPTOR; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; ALOPECIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETCHING; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ALOPECIA; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONSTIPATION; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; ONDANSETRON; PIPERAZINES; PIPERIDINES; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME; VOMITING;

EID: 73949158930     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8511     Document Type: Article

References (18)

1. Sun CC, Bodurka DC, Weaver CB, et al: Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227, 2005
2. Grunberg SM, Deuson RR, Mavros P, et al: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261-2268, 2004
3. Liau CT, Chu NM, Liu HE, et al: Incidence of chemotherapy-induced nausea and vomiting in Taiwan: Physicians' and nurses' estimation vs. patients' reported outcomes. Support Care Cancer 13:277-286, 2005
4. Neymark N, Crott R: Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: A retrospective analysis of three clinical trials. Support Care Cancer 13:812-818, 2005
5. Richardson JL, Marks G, Levine A: The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. J Clin Oncol 6:1746-1752, 1988
6. Cohen L, de Moor CA, Eisenberg P, et al: Chemotherapy-induced nausea and vomiting: Incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503, 2007
7. Schnell FM: Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 8:187-198, 2003
8. Hesketh PJ, Van Belle S, Aapro M, et al: Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074-1080, 2003
9. Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816-821, 1990
10. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: Results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003
11. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003
12. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005
13. Arpornwirat W, Albert I, Hansen VL, et al: Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 24:471s, 2006 (abstr 8512)
14. Grunberg SM, Osoba D, Hesketh PJ, et al: Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: An update. Support Care Cancer 13:80-84, 2005
15. Center for Drug Evaluation and Research: E6 Good clinical practice: Consolidated guidance. ICH April 1996. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm073122.pdf
16. International Conference on Harmonisation: Guidelines. https://www.ich.org/cache/html/250-272-1.html
17. Booth CM, Clemons M, Dranitsaris G, et al: Chemotherapy-induced nausea and vomiting in breast cancer patients: A prospective observational study. J Support Oncol 5:374-380, 2007
18. Johnson BM, Hoke JF, Bandekar RR, et al: Pharmacokinetics and pharmacokodynamics of casopitant, an NK-1 receptor antagonist, in patients undergoing treatment with moderately and highly-emetogenic chemotherapy. Clin Pharmacol Ther 81, 2007 (abstr)